THERAPY DOSSIER · th-284ccc47c915

Human induced pluripotent stem cell-derived neural cells on a hybrid microfluidic nanofibre scaffold (PDMS microgrooves on biodegradable polymer)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26914600 ↗2016Mixed findings

A hybrid microfluidic system for regulation of neural differentiation in induced pluripotent stem cells.

RatSpinal cord injuryHemisection / partialWistarFemaleImplantation of the cell-seeded scaffold into the hemisected spinal cordAcute phase, at the time of hemisection

Model: Acute spinal cord hemisection

Neuronal-specific gene expression was significantly higher on the microfluidic device than on control systems, and implanted cells survived and integrated, but this did not lead to significant locomotor recovery.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…